Bejelentkezés Regisztrálj ingyen

Last updated: 18 June 2020 at 8:35am EST

Michael Venuti Net Worth




The estimated Net Worth of Michael C Venuti is at least $22.8 ezer dollars as of 17 March 2017. Michael Venuti owns over 6,250 units of Infinity Pharmaceuticals stock worth over $1,000 and over the last 18 years he sold INFI stock worth over $21,750. In addition, he makes $0 as Independent Director at Infinity Pharmaceuticals.

Michael Venuti INFI stock SEC Form 4 insiders trading

Michael has made over 2 trades of the Infinity Pharmaceuticals stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 6,250 units of INFI stock worth $21,750 on 17 March 2017.

The largest trade he's ever made was selling 6,250 units of Infinity Pharmaceuticals stock on 17 March 2017 worth over $21,750. On average, Michael trades about 735 units every 87 days since 2006. As of 17 March 2017 he still owns at least 50,000 units of Infinity Pharmaceuticals stock.

You can see the complete history of Michael Venuti stock trades at the bottom of the page.





Michael Venuti biography

DR. Michael C. Venuti Ph.D. serves as Independent Director of the Company. Dr. Venuti has served as a member of our board of directors and the board of directors of our predecessor company since May 2003. Prior to becoming a scientific consultant in January 2014, Dr. Venuti served as the Chief Scientific Officer of NeuroTherapeutics Pharma, Inc., a privately held biopharmaceutical company, from July 2011 to March 2013. Prior to NeuroTherapeutics, Dr. Venuti served as President, Chief Executive Officer and a director of iPierian, Inc., a privately held biopharmaceutical company, between July 2010 and April 2011 after joining iPierian as President and Chief Scientific Officer in February 2010. Dr. Venuti was Chief Executive Officer and Director of BioSeek, Inc., a privately held drug discovery company, from November 2007 to February 2010. Prior to that, Dr. Venuti was an Operating Manager at TPG Growth Biotech Ventures, a private equity firm, from January through June 2007. Dr. Venuti served as the Acting Chief Executive Officer of our predecessor company prior to its merger with Infinity Discovery Inc. in September 2006, and as its Chief Scientific Officer from April 2005 through September 2006. Prior to that, he was Senior Vice President of Pharmacogenomics, and was named Senior Vice President of Research and General Manager of Celera South San Francisco when the Celera Genomics Group of Applera Corporation, a life sciences company, acquired Axys Pharmaceuticals, Inc. in 2001. From 1994 through 2001, Dr. Venuti was Director of Medicinal Chemistry, and then Chief Technical Officer, for Axys Pharmaceuticals and its predecessor company, Arris Pharmaceutical Corporation.



How old is Michael Venuti?

Michael Venuti is 66, he's been the Independent Director of Infinity Pharmaceuticals since 2006. There are 4 older and 13 younger executives at Infinity Pharmaceuticals. The oldest executive at Infinity Pharmaceuticals Inc. is Anthony Evnin, 79, who is the Independent Director.

What's Michael Venuti's mailing address?

Michael's mailing address filed with the SEC is C/O INFINITY PHARMACEUTICALS, INC., 1100 MASSACHUSETTS AVENUE, FLOOR 4, CAMBRIDGE, MA, 02138.

Insiders trading at Infinity Pharmaceuticals

Over the last 18 years, insiders at Infinity Pharmaceuticals have traded over $485,846,497 worth of Infinity Pharmaceuticals stock and bought 22,639,120 units worth $175,155,554 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... és Medical Co L.P. Rosebay. On average, Infinity Pharmaceuticals executives and independent directors trade stock every 70 days with the average trade being worth of $14,976. The most recent stock trade was executed by Adelene Q Perkins on 8 September 2023, trading 768,133 units of INFI stock currently worth $15,363.



What does Infinity Pharmaceuticals do?

the mission of infinity pharmaceuticals, inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation. small molecule discovery and development capabilities infinity’s programs arise from the integration of a broad range of research and development capabilities, including strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation. strategic alliances building on its strengths in innovative small molecule drug discovery and development, infinity has established significant alliances with leading pharmaceutical and biotechnology companies to help realize the full potential of its product pipeline. business and scientific expertise the company has assembled a team of passionate, committed, and innovative individuals who bring together their collective expertise in all areas of business



What does Infinity Pharmaceuticals's logo look like?

Infinity Pharmaceuticals Inc. logo

Complete history of Michael Venuti stock trades at Infinity Pharmaceuticals

Dátum
#
Cég
 Az érdekelt
Trans.
Tranzakció
 Részvények száma Ár per részvény Teljes ár Részvények szíma után Forrás
17 Mar 2017 INFI Infinity Pharmaceuticals Inc. Michael C Venuti
Rendező
 Eladás 6,250 $3.48 $21,750
17 Mar 2017
50,000 ↗
6 Mar 2013 INFI Infinity Pharmaceuticals Inc. Michael C Venuti
Rendező
 Opció Gyakorlat 6,250 $16.80 $105,000
6 Mar 2013
56,250 ↗


Infinity Pharmaceuticals executives and stock owners

Infinity Pharmaceuticals executives and other stock owners filed with the SEC include: